cIMPACT-NOW更新及其对当前神经肿瘤学实践的意义。
The cIMPACT-NOW updates and their significance to current neuro-oncology practice.
作者信息
Gonzalez Castro L Nicolas, Wesseling Pieter
机构信息
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
出版信息
Neurooncol Pract. 2020 Aug 29;8(1):4-10. doi: 10.1093/nop/npaa055. eCollection 2021 Feb.
Abstract
Over the past 4 years, advances in molecular pathology have enhanced our understanding of CNS tumors, providing new elements to refine their classification and improve the 2016 World Health Organization (WHO) Classification of CNS tumors. The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO (cIMPACT-NOW) was formed in late 2016 by a group of neuropathology and neuro-oncology experts to provide practical recommendations (published as cIMPACT-NOW updates) to improve the diagnosis and classification of CNS tumors, in advance of the publication of a new WHO Classification of CNS tumors. Here we review the content of all the available cIMPACT-NOW updates and discuss the implications of each update for the diagnosis and management of patients with CNS tumors.
摘要
在过去4年中，分子病理学的进展加深了我们对中枢神经系统肿瘤的理解，为完善其分类并改进2016年世界卫生组织（WHO）中枢神经系统肿瘤分类提供了新的要素。2016年末，一组神经病理学和神经肿瘤学专家成立了中枢神经系统肿瘤分类分子与实践方法咨询联盟——非WHO官方组织（cIMPACT-NOW），以便在新版WHO中枢神经系统肿瘤分类发布之前，提供实用建议（以cIMPACT-NOW更新版形式发布），以改善中枢神经系统肿瘤的诊断和分类。在此，我们回顾了所有可用的cIMPACT-NOW更新版内容，并讨论了每次更新对中枢神经系统肿瘤患者诊断和管理的影响。
相似文献
1
The cIMPACT-NOW updates and their significance to current neuro-oncology practice.
Neurooncol Pract. 2020 Aug 29;8(1):4-10. doi: 10.1093/nop/npaa055. eCollection 2021 Feb.
2
Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5.
Int J Gen Med. 2023 Jan 7;16:107-127. doi: 10.2147/IJGM.S394872. eCollection 2023.
3
What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW.
J Neuropathol Exp Neurol. 2019 Apr 1;78(4):294-296. doi: 10.1093/jnen/nlz012.
4
[Molecular Diagnostic Approaches for Diffuse Gliomas Based on Updated WHO Classification and cIMPACT-NOW Proposals].
No Shinkei Geka. 2021 May;49(3):510-519. doi: 10.11477/mf.1436204423.
5
cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates.
Brain Pathol. 2019 Jul;29(4):469-472. doi: 10.1111/bpa.12732. Epub 2019 May 22.
6
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.
Brain Pathol. 2020 Jul;30(4):844-856. doi: 10.1111/bpa.12832. Epub 2020 Apr 19.
7
Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System.
Int J Clin Oncol. 2020 Jun;25(6):997-1003. doi: 10.1007/s10147-020-01695-w. Epub 2020 May 28.
8
Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment.
Cancers (Basel). 2021 Feb 12;13(4):758. doi: 10.3390/cancers13040758.
9
Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Curr Opin Neurol. 2020 Dec;33(6):701-706. doi: 10.1097/WCO.0000000000000871.
10
Pearls and Pitfalls of Imaging in Pediatric Brain Tumors.
Semin Ultrasound CT MR. 2022 Feb;43(1):31-46. doi: 10.1053/j.sult.2021.05.004. Epub 2021 May 15.
引用本文的文献
1
New Approach for Enhancing Survival in Glioblastoma Patients: A Longitudinal Pilot Study on Integrative Oncology.
Cancers (Basel). 2025 Jul 12;17(14):2321. doi: 10.3390/cancers17142321.
2
Clinico-Pathological Features of Diffuse Midline Glioma, H3 K27-Altered in Adults: A Comprehensive Review of the Literature with an Additional Single-Institution Case Series.
Diagnostics (Basel). 2024 Nov 21;14(23):2617. doi: 10.3390/diagnostics14232617.
3
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice.
Lancet Oncol. 2024 Nov;25(11):e589-e601. doi: 10.1016/S1470-2045(24)00315-2.
4
European Association of Neuro-Oncology's 30th anniversary: A successful and growing relationship with .
Neurooncol Pract. 2024 Aug 10;11(5):509-510. doi: 10.1093/nop/npae061. eCollection 2024 Oct.
5
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.
Neuro Oncol. 2025 Feb 10;27(2):319-330. doi: 10.1093/neuonc/noae170.
6
Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
Int J Mol Sci. 2024 Jul 21;25(14):7974. doi: 10.3390/ijms25147974.
7
What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas.
Ann Afr Med. 2024 Jul 1;23(3):255-261. doi: 10.4103/aam.aam_63_23. Epub 2024 Jul 20.
8
H3-Altered Diffuse Glioma of the Spinal Cord in Adult Patients: A Qualitative Systematic Review and Peculiarity of Radiological Findings.
J Clin Med. 2024 May 18;13(10):2972. doi: 10.3390/jcm13102972.
9
New insights into targeted therapy of glioblastoma using smart nanoparticles.
Cancer Cell Int. 2024 May 7;24(1):160. doi: 10.1186/s12935-024-03331-3.
10
Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.
AJNR Am J Neuroradiol. 2024 Aug 9;45(8):1006-1012. doi: 10.3174/ajnr.A8225.
本文引用的文献
1
cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.
Brain Pathol. 2020 Sep;30(5):863-866. doi: 10.1111/bpa.12866. Epub 2020 Jun 23.
2
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.
Brain Pathol. 2020 Jul;30(4):844-856. doi: 10.1111/bpa.12832. Epub 2020 Apr 19.
3
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
4
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Neuro Oncol. 2020 Apr 15;22(4):515-523. doi: 10.1093/neuonc/noz200.
5
Molecular pathology of tumors of the central nervous system.
Ann Oncol. 2019 Aug 1;30(8):1265-1278. doi: 10.1093/annonc/mdz164.
6
cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates.
Brain Pathol. 2019 Jul;29(4):469-472. doi: 10.1111/bpa.12732. Epub 2019 May 22.
7
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation.
Acta Neuropathol. 2019 Apr;137(4):683-687. doi: 10.1007/s00401-019-01987-0. Epub 2019 Mar 8.
8
What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW.
J Neuropathol Exp Neurol. 2019 Apr 1;78(4):294-296. doi: 10.1093/jnen/nlz012.
9
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
10
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience.
Acta Neuropathol. 2018 Aug;136(2):181-210. doi: 10.1007/s00401-018-1879-y. Epub 2018 Jul 2.
Zotero 插件